Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fermenta BiotechNSE:FERMENTA 54 Days Payable is 121.47 as of Jun. 2026, which is 14% below its 10-year median of 140.60. GuruFocus rates NSE:FERMENTA with a GF Score™ of 54/100 and a GF Value™ of ₹315.37 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Fermenta Biotech ranks better than 70.1% on this metric.
The historical rank and industry rank for Fermenta Biotech's Days Payable or its related term are showing as below:
NSE:FERMENTA'
s Days Payable Range Over the Past 10 Years
Min: 101.33 Med: 140.6 Max: 203.19
Current: 131.58
During the past 13 years, Fermenta Biotech's highest Days Payable was 203.19. The lowest was 101.33. And the median was 140.60.
NSE:FERMENTA's Days Payable is ranked better than 70.1% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.47
vs NSE:FERMENTA: 131.58
Fermenta Biotech's Days Payable
increased
from Jun. 2025 (105.44) to Jun. 2026 (121.47).
It may suggest that Fermenta Biotechdelayed paying its suppliers.
The historical data trend for Fermenta Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fermenta Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fermenta Biotech Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fermenta Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Fermenta Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fermenta Biotech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fermenta Biotech (NSE:FERMENTA) has a Days Payable of 121.47 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fermenta Biotech and its competitors. This is 14% below median its historical median of 140.60. Over the past decade, Fermenta Biotech's Days Payable has ranged from 101.33 to 203.19. According to the industry distribution chart, Fermenta Biotech ranks #276 out of 923 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Fermenta Biotech's Days Payable too high?
Fermenta Biotech's current Days Payable of 121.47 is 14% below median its 10-year median of 140.60. Over the past 10 years, this metric has ranged from a low of 101.33 to a high of 203.19. The Drug Manufacturers industry median Days Payable is 88.47. Fermenta Biotech's value of 121.47 is 37.3% above this industry median. Based on the distribution chart, Fermenta Biotech ranks #276 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fermenta Biotech has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fermenta Biotech's Days Payable compare to ?
According to the Drug Manufacturers industry distribution chart, Fermenta Biotech ranks #276 out of 923 companies for Days Payable. This puts Fermenta Biotech in the upper half of its industry. The industry median Days Payable is 88.47. Fermenta Biotech's value of 121.47 is 37.3% above this benchmark. Historically, Fermenta Biotech's own Days Payable has ranged from 101.33 to 203.19 over the past decade. While the company's 10-year median is 140.60 vs. the industry median of 88.47, Fermenta Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.47, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fermenta Biotech's current Days Payable of 121.47 is 37.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fermenta Biotech and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fermenta Biotech's current Days Payable is 121.47, which is 14% below median its own 10-year median of 140.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fermenta Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fermenta Biotech (NSE:FERMENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹315.37, compared to a current price of ₹456.10 — trading 44.6% above its estimated fair value. The current Days Payable is 121.47, which is 14% below median its 10-year median of 140.60 and 37.3% above the Drug Manufacturers industry median of 88.47. Fermenta Biotech's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fermenta Biotech (NSE:FERMENTA), the current Days Payable is 121.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fermenta Biotech (NSE:FERMENTA) Overvalued in 2026?
Based on GuruFocus' analysis, Fermenta Biotech stock appears to be overvalued.
The current stock price of ₹456.10 is trading 44.6% above its estimated GF Value™ of ₹315.37.
GuruFocus considers Fermenta Biotech to be Significantly Overvalued.
Key valuation signals for NSE:FERMENTA:
Days Payable: 121.47 (14% below median its 10-year median of 140.60)
GF Value™: ₹315.37 vs. price of ₹456.10 (44.6% above fair value)
Industry Position: 37.3% above the Drug Manufacturers median (#276 of 923)
No single metric tells the full story. See the NSE:FERMENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fermenta Biotech Ltd is engaged in the business of manufacturing and marketing chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products and renting and selling properties. It is a manufacturer and supplier of Vitamin D and also supplies Penicillin G Amidase, CAL B Lipase, Polymer Supports, and enzyme technologies. The company operates in two segments namely Property and Bulk Drugs/Chemicals. The majority of the revenue comes from the Bulk Drug/Chemicals segment. Geographically, it caters to both domestic and international markets and generates maximum revenue from the Indian market.
54GF Score
Get the complete analysis for NSE:FERMENTA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:FERMENTA has been successfully added to your 
